Immuno_oncology-Pharmacodynamics

Tryptophan-Kynurenine Pathway in Immuno-Oncology

Rima Ait-Belkacem (1), Vanesa Bol (2), Gregory Hamm (1), Florence Schramme (3), Benoit Van Den Eynde (3), Lauranne Poncelet (1), Fabien Pamelard (1), Jonathan Stauber (1), Bruno Gomes (2)
Methods Mol Biol. 2010

1 ImaBiotech, MS Imaging Department, Lille, France
2 Iteos Therapeutics, Gosselies, Belgium
3 Ludwig Institute for Cancer Research, Brussels, Belgium

Abstract
Inhibition of NK and effector T-cell functions and activation of regulatory cell populations are the main immunosuppressive effects of indoleamine-2,3-dioxygenase1 (IDO1). By converting tryptophan (Trp) into kynurenine (Kyn), IDO1 is involved in the immune response homeostasis, and its dysregulated expression is described in immune-related pathologies, as tumors that hijack it to evade immune destruction. Thereby, IDO1 inhibitors are being developed to stimulate antitumor immune responses. Existing and standard quantitation methods of IDO1 substrate and metabolite(s) are based on the total level of Trp and its metabolites determined by liquid chromatography tandem mass spectrometry analysis in human plasma, cerebrospinal fluid, and brain. Here, we describe the detection, localization, and absolute quantitation of Trp and Kyn by quantitative mass spectrometry imaging (qMSI) in transfected murine tumor models expressing various levels of IDO1. Myeloid, glycolysis metabolic signatures, and correlation between IDO1 expression and Trp to Kyn conversion are also shown. High-definition IDO1 and GCN2 immunostainings overlaid with Kyn molecular images underline the tumor metabolism and heterogeneity. The development of immunotherapies such as IDO1 inhibitors requires a deep understanding of the immune system, the interplay of cancer cells, and biomarker characterization. Our data underline that qMSI allows the study of the spatial distribution and quantitation of endogenous immune metabolites for biology and pharmacology studies.

Read more




Search news